The Future Of Adcs

Kristen Ciombor, MD, MSCI, Vanderbilt-Ingram Cancer Center, Nashville, TN, discusses the potential role antibody-drug ...

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses the emerging ...

Dr. Jason Mouabbi and Dr. Eric Singhi discuss

Yale Cancer Center Grand Rounds | January 28, 2-25 Presented by: Dr. Ian Krop.

This session occurred on Wednesday, Dec. 11, 2024. It was an Education Session YOUTUBE CHAPTERS 0:00 Introduction by ...

Drs Ursula Matulonis and Brian Slomovitz discuss phase 3 trials of

Ka Yu Tse, MBBS, The University of Hong Kong, Hong Kong, China, comments on the potential role of PARP inhibitors with ...

A new generation of HER2-targeted therapy is changing the treatment landscape for gastric and gastroesophageal junction (GEJ) ...

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, delves into

Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, comments on novel ...

Melissa Calopiz, University of Michigan, Ann Arbor, MI, reviews the different ways to optimize antibody-drug conjugate (

Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, comments on the potential of antibody drug conjugates ...

Antibody Drug Conjugates (

Stay tuned for insights that will help shape

Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, comments ...

In this video, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, ...

Did you know that, while well established in the metastatic setting, second-generation antibody-drug conjugates are now moving ...

Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses how

Future ADCs

Romness claims that